Dermatologic DiseasesNCT07640763
Daily Screen Time Exposure in Dermatology Patients
An observational study of Dermatologic Diseases and Outpatient Clinics, Hospital, run by Biruni University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to determine the daily screen time (smartphone, computer/tablet and television) of all patients who visited a tertiary dermatology outpatient clinic within a specific period and to evaluate differences in screen time duration among various dermatological diagnoses, to assess whether higher… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Dermatologic Diseases, Outpatient Clinics, Hospital
- How many people
- 319 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 26 Jan 2026to 1 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All patients who visited the dermatology outpatient clinic of a tertiary university hospital were evaluated for the study.
Who may be able to join
- Patients aged ≥18 years
- Patients attending the dermatology outpatient clinic
- Ability to understand and answer the questions
- Voluntary participation with informed consent
Who cannot join
- Patients younger than 18 years
- Patients with cognitive impairment preventing questionnaire completion
- Incomplete data
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Biruni University Hospital
Küçükçekmece, Istanbul
About this study
Official title: Evaluation of Daily Screen Time Exposure in Patients Attending a Dermatology Outpatient Clinic: A Cross-Sectional Study
The aim of this study is to determine the daily screen time (smartphone, computer/tablet and television) of all patients who visited a tertiary dermatology outpatient clinic within a specific period and to evaluate differences in screen time duration among various dermatological diagnoses, to assess whether higher screen time exposure is associated with specific dermatological conditions.
Read the detailed description
All patients who visited the dermatology outpatient clinic of a tertiary university hospital were evaluated for the study. Patients aged over 18 years, attending to dermatology outpatient clinic, able to understand and answer the questions, voluntarily participated by giving informed consent were included. Data was collected using a structured, questionnaire completed by the dermatologist during the outpatient visit. The questionnaire consisted of three main sections:
- Demographic data: age, sex, date of survey.
- Clinical diagnosis: Dermatologist diagnosed one or more dermatological disorder during examination including acne vulgaris, atopic dermatitis, seborrheic dermatitis, rosacea, irritant contact dermatitis, viral warts, non-neoplastic melanocytic nevus, urticaria, pigmentation disorders, androgenetic alopecia, acrocordon, pyoderma, abscess, epidermal cyst, telogen effluvium, alopecia areata, etc.
- Participants reported their average daily screen time over the past 6 months for: smartphone use, computer/tablet use, television viewing. Screen time was categorized as: 0, 0-1, 1-3, 3-5, 5-7, 7-9, 9-11, 11-13, 13-15, 15-17, 17-19, 19-21, 21-23 hours per day. Total daily screen time was calculated by summing up different device usage categories. Minimum and maximum values were summed separately.
- Keywords
- dermatology, screen time, smartphone use, digital devices, lifestyle factors, outpatient clinic
- Medical subject headings
- Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| dermatology outpatients | It is expected to provide descriptive data on screen time exposure among dermatology outpatients and identify potential associations between screen usage patterns and dermatological diagnoses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Smartphone screen time (hours/day), Computer/tablet screen time (hours/day), Television viewing time (hours/day), Total daily screen time
Measured: baseline
Dermatological diagnosis
diagnosed by the dermatologist
Measured: baseline
Secondary outcomes (1)
demographic data
Age, Sex
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2026
- Study start26 Jan 2026
- Primary completion31 Mar 2026
- Study completion1 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dermatologic DiseasesStudies of the same condition, open and under way.
- More trials run by Biruni UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 319 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biruni University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07640763
- Sponsor's protocol ID
- Screen time
- Status last verified
- May 2026
- First submitted
- 15 May 2026
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Daily Screen Time Exposure in Patients Attending a Dermatology Outpatient Clinic: A Cross-Sectional Study
- ClinicalTrials.gov ID
- NCT07640763
- Acronym / sponsor ID
- Screen time
- Keywords
- dermatology, screen time, smartphone use, digital devices, lifestyle factors, outpatient clinic
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 319 participants (actual)
- Lead sponsor
- Biruni UniversityUniversity, hospital or other
- Study start
- 26 Jan 2026 (actual)
- Primary completion
- 31 Mar 2026 (actual)
- Study completion
- 1 May 2026 (actual)
- First posted
- 11 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to determine the daily screen time (smartphone, computer/tablet and television) of all patients who visited a tertiary dermatology outpatient clinic within a specific period and to evaluate differences in screen time duration among various dermatological diagnoses, to assess whether higher screen time exposure is associated with specific dermatological conditions.
Detailed description
All patients who visited the dermatology outpatient clinic of a tertiary university hospital were evaluated for the study. Patients aged over 18 years, attending to dermatology outpatient clinic, able to understand and answer the questions, voluntarily participated by giving informed consent were included. Data was collected using a structured, questionnaire completed by the dermatologist during the outpatient visit. The questionnaire consisted of three main sections:
- Demographic data: age, sex, date of survey.
- Clinical diagnosis: Dermatologist diagnosed one or more dermatological disorder during examination including acne vulgaris, atopic dermatitis, seborrheic dermatitis, rosacea, irritant contact dermatitis, viral warts, non-neoplastic melanocytic nevus, urticaria, pigmentation disorders, androgenetic alopecia, acrocordon, pyoderma, abscess, epidermal cyst, telogen effluvium, alopecia areata, etc.
- Participants reported their average daily screen time over the past 6 months for: smartphone use, computer/tablet use, television viewing. Screen time was categorized as: 0, 0-1, 1-3, 3-5, 5-7, 7-9, 9-11, 11-13, 13-15, 15-17, 17-19, 19-21, 21-23 hours per day. Total daily screen time was calculated by summing up different device usage categories. Minimum and maximum values were summed separately.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| dermatology outpatients | – | –It is expected to provide descriptive data on screen time exposure among dermatology outpatients and identify potential associations between screen usage patterns and dermatological diagnoses |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All patients who visited the dermatology outpatient clinic of a tertiary university hospital were evaluated for the study.
Key inclusion criteria (4 listed)
- Patients aged ≥18 years
- Patients attending the dermatology outpatient clinic
- Ability to understand and answer the questions
- Voluntary participation with informed consent
Key exclusion criteria (3 listed)
- Patients younger than 18 years
- Patients with cognitive impairment preventing questionnaire completion
- Incomplete data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Smartphone screen time (hours/day), Computer/tablet screen time (hours/day), Television viewing time (hours/day), Total daily screen time
Time frame: baseline
Dermatological diagnosis
Time frame: baseline
diagnosed by the dermatologist
1 secondary outcome
demographic data
Time frame: baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Dermatologic Diseases
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dermatologic Diseases and Outpatient Clinics, Hospital, run by Biruni University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Smartphone screen time (hours/day), Computer/tablet screen time (hours/day), Television viewing time (hours/day), Total daily screen time (time frame: baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.